Literature DB >> 11359858

Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia.

M Sata1, Z Luo, K Walsh.   

Abstract

Despite recent advances in immunosuppressive therapy, accelerated coronary atherosclerosis remains a major problem in the long-term survival of transplant recipients. Chronic graft vasculopathy is believed to result from recipient inflammatory responses, and it is characterized by early mononuclear cell infiltration of the transplanted vessel. Here we show that endothelial cells can be genetically modified to overexpress functional, cell-surface Fas ligand (FasL) by adenovirus-mediated gene transfer without undergoing self-destruction. In a rodent model of transplant graft vasculopathy, endothelial overexpression of FasL attenuated T cell and macrophage infiltration at 1 wk posttransplantation. These vessels also displayed reduced neointima formation at one and 2 mo posttransplantation. These results indicate that inhibition of the early inflammatory response to allografted vessels by endothelial cell-specific overexpression of FasL may have utility in the treatment of transplant arteriosclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11359858     DOI: 10.4049/jimmunol.166.11.6964

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Endothelial Fas-Ligand in Inflammatory Bowel Diseases and in Acute Appendicitis.

Authors:  Tuomo S Kokkonen; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2015-09-15       Impact factor: 2.479

2.  Fas ligand and nitric oxide combination to control smooth muscle growth while sparing endothelium.

Authors:  Mehmet H Kural; Juan Wang; Liqiong Gui; Yifan Yuan; Guangxin Li; Katherine L Leiby; Elias Quijano; George Tellides; W Mark Saltzman; Laura E Niklason
Journal:  Biomaterials       Date:  2019-05-07       Impact factor: 12.479

Review 3.  The intragraft microenvironment as a central determinant of chronic rejection or local immunoregulation/tolerance.

Authors:  Johannes Wedel; Hironao Nakayama; Nora M Kochupurakkal; Josephine Koch; Michael Klagsbrun; Diane R Bielenberg; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

4.  Dendritic cells overexpressing Fas-ligand induce pulmonary vasculitis in mice.

Authors:  S Buonocore; V Flamand; N Claessen; P Heeringa; M Goldman; S Florquin
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

Review 5.  Coronary artery vasculopathy in pediatric cardiac transplant patients: the therapeutic potential of immunomodulators.

Authors:  Biagio Pietra; Mark Boucek
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Recombinant adenoviral gene transfer does not affect cardiac allograft vasculopathy.

Authors:  Vinay P Rao; Stefano E Branzoli; Davide Ricci; Naoto Miyagi; Timothy O'Brien; Henry D Tazelaar; Stephen J Russell; Christopher G A McGregor
Journal:  J Heart Lung Transplant       Date:  2007-12       Impact factor: 10.247

7.  Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.

Authors:  Jie Hui Li; Martin S Kluger; Lisa A Madge; Lian Zheng; Alfred L M Bothwell; Jordan S Pober
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

8.  Oxidative stress increases Fas ligand expression in endothelial cells.

Authors:  Mayumi Suzuki; Kazutetsu Aoshiba; Atsushi Nagai
Journal:  J Inflamm (Lond)       Date:  2006-07-19       Impact factor: 4.981

Review 9.  Extracellular hemoglobin: the case of a friend turned foe.

Authors:  Isaac K Quaye
Journal:  Front Physiol       Date:  2015-04-20       Impact factor: 4.566

10.  Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.

Authors:  Gregory T Motz; Stephen P Santoro; Li-Ping Wang; Tom Garrabrant; Ricardo R Lastra; Ian S Hagemann; Priti Lal; Michael D Feldman; Fabian Benencia; George Coukos
Journal:  Nat Med       Date:  2014-05-04       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.